Literature DB >> 19073907

Regulation of T-cell function by endogenously produced angiotensin II.

Nyssa E Hoch1, Tomasz J Guzik, Wei Chen, Tenecia Deans, Samer A Maalouf, Petra Gratze, Cornelia Weyand, David G Harrison.   

Abstract

The adaptive immune response and, in particular, T cells have been shown to be important in the genesis of hypertension. In the present study, we sought to determine how the interplay between ANG II, NADPH oxidase, and reactive oxygen species modulates T cell activation and ultimately causes hypertension. We determined that T cells express angiotensinogen, the angiotensin I-converting enzyme, and renin and produce physiological levels of ANG II. AT1 receptors were primarily expressed intracellularly, and endogenously produced ANG II increased T-cell activation, expression of tissue homing markers, and production of the cytokine TNF-alpha. Inhibition of T-cell ACE reduced TNF-alpha production, indicating endogenously produced ANG II has a regulatory role in this process. Studies with specific antagonists and T cells from AT1R and AT2R-deficient mice indicated that both receptor subtypes contribute to TNF-alpha production. We found that superoxide was a critical mediator of T-cell TNF-alpha production, as this was significantly inhibited by polyethylene glycol (PEG)-SOD, but not PEG-catalase. Thus, T cells contain an endogenous renin-angiotensin system that modulates T-cell function, NADPH oxidase activity, and production of superoxide that, in turn, modulates TNF-alpha production. These findings contribute to our understanding of how ANG II and T cells enhance inflammation in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073907      PMCID: PMC2643984          DOI: 10.1152/ajpregu.90521.2008

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  46 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors.

Authors:  Gunter Wolf; Ulrich Wenzel; Kevin D Burns; Raymond C Harris; Rolf A K Stahl; Friedrich Thaiss
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

3.  Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis.

Authors:  Vera Jankowski; Raymond Vanholder; Markus van der Giet; Lars Henning; Markus Tölle; Gilbert Schönfelder; Anja Krakow; Sevil Karadogan; Niklas Gustavsson; Johan Gobom; Jessie Webb; Hans Lehrach; Günther Giebing; Hartmut Schlüter; Karl F Hilgers; Walter Zidek; Joachim Jankowski
Journal:  Hypertension       Date:  2005-08-08       Impact factor: 10.190

4.  Levels of plasma angiotensin-(1-7) in patients with hypertension who have the angiotensin-I-converting enzyme deletion/deletion genotype.

Authors:  Jorge E Jalil; Cristián Palomera; María Paz Ocaranza; Iván Godoy; Maritza Román; Mario Chiong; Sergio Lavandero
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

5.  Angiotensin II subtype 1A (AT1A) receptors in the rat sensory vagal complex: subcellular localization and association with endogenous angiotensin.

Authors:  J Huang; Y Hara; J Anrather; R C Speth; C Iadecola; V M Pickel
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 6.  The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

Authors:  Hua Cai; Kathy K Griendling; David G Harrison
Journal:  Trends Pharmacol Sci       Date:  2003-09       Impact factor: 14.819

7.  Renal expression of angiotensin type 2 (AT2) receptors during kidney damage.

Authors:  Marta Ruiz-Ortega; Vanesa Esteban; Yusuke Suzuki; Mónica Ruperez; Sergio Mezzano; Leopoldo Ardiles; Pilar Justo; Alberto Ortiz; Jesús Egido
Journal:  Kidney Int Suppl       Date:  2003-10       Impact factor: 10.545

8.  Captopril prevents experimental autoimmune myocarditis.

Authors:  Lisa M Godsel; Juan S Leon; Kegiang Wang; Jamie L Fornek; Agostino Molteni; David M Engman
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.

Authors:  Vanesa Esteban; Oscar Lorenzo; Mónica Rupérez; Yusuke Suzuki; Sergio Mezzano; Julia Blanco; Mathias Kretzler; Takeshi Sugaya; Jesús Egido; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

Review 10.  Recent advances in angiotensin II signaling.

Authors:  R M Touyz; C Berry
Journal:  Braz J Med Biol Res       Date:  2002-08-30       Impact factor: 2.590

View more
  131 in total

1.  Identification of the primary outcomes that result from deficient spiral arterial modification in pregnant mice.

Authors:  B Anne Croy; Suzanne D Burke; Valerie F Barrette; Jianhong Zhang; Kota Hatta; Graeme N Smith; Juares Bianco; Aureo T Yamada; Michael A Adams
Journal:  Pregnancy Hypertens       Date:  2011-01-01       Impact factor: 2.899

2.  Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide.

Authors:  Tanya M Gwathmey; Brian M Westwood; Nancy T Pirro; Lijun Tang; James C Rose; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

3.  Therapeutic targeting of mitochondrial superoxide in hypertension.

Authors:  Anna E Dikalova; Alfiya T Bikineyeva; Klaudia Budzyn; Rafal R Nazarewicz; Louise McCann; William Lewis; David G Harrison; Sergey I Dikalov
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

Review 4.  The central nervous system and inflammation in hypertension.

Authors:  Paul J Marvar; Heinrich Lob; Antony Vinh; Faresa Zarreen; David G Harrison
Journal:  Curr Opin Pharmacol       Date:  2010-12-31       Impact factor: 5.547

5.  Innate Immune Cells Are Regulated by Axl in Hypertensive Kidney.

Authors:  Sri N Batchu; George J Dugbartey; Kristine M Wadosky; Deanne M Mickelsen; Kyung A Ko; Ronald W Wood; Yuqi Zhao; Xia Yang; Deborah J Fowell; Vyacheslav A Korshunov
Journal:  Am J Pathol       Date:  2018-08       Impact factor: 4.307

6.  Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils.

Authors:  Zakir Khan; Xiao Z Shen; Ellen A Bernstein; Jorge F Giani; Masahiro Eriguchi; Tuantuan V Zhao; Romer A Gonzalez-Villalobos; Sebastien Fuchs; George Y Liu; Kenneth E Bernstein
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

7.  Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia.

Authors:  Hizir Kurtel; Stephen F Rodrigues; Cigdem E Yilmaz; Alper Yildirim; D Neil Granger
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

Review 8.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

Review 9.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

10.  Loss of Resistance to Angiotensin II-Induced Hypertension in the Jackson Laboratory Recombination-Activating Gene Null Mouse on the C57BL/6J Background.

Authors:  Hong Ji; Amrita V Pai; Crystal A West; Xie Wu; Robert C Speth; Kathryn Sandberg
Journal:  Hypertension       Date:  2017-04-24       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.